Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of zibotentan + dapagliflozin versus dapagliflozin in chronic kidney disease with high proteinuria
jRCT2031230557Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of zibotentan and dapagliflozin in chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Started Mar 2024; status: active, not recruiting.
02
Drugs
zibotentandapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031230557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230557.